Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Post by letsgo111on Feb 13, 2024 3:04am
234 Views
Post# 35876875

Far out question for the experts here

Far out question for the experts hereSo safe to say PMN is struggling with making progress getting FDA approval.  Not a knock against them, they could have an game changing product.

But is this the only way forward?  If it is and the only way to achieve that is to be bought by a larger company that can pay for the approval (judging from Biogen, approvals are purchased and probably gatekept) would it be possible to attempt to gain approval in other countries?  If, I don't know, say Brazil begins accepting the use of PMN 310 for Alzheimer's patients that volunteer to try it, possibly as a last resort - could success there snowball further?  Could it, if it's having success treating patients, put pressure on the FDA?  There must be countries that would be willing to have their alzheimer's patients / families at least given the option to try cutting edge tech.  Promis may need to guarantee the country's government the medication at a specific price for the next X years so if the medication is successful, they stand to win in some sense.

Food for thought.  Am I crazy here?
<< Previous
Bullboard Posts
Next >>